Heparin-associated thrombocytopenia treatment with low molecular weight heparin.
Eight patients with heparin associated thrombocytopenia (HAT) were treated by a low molecular weight heparin derivative (LMW). Biological and clinical improvement occurred in all patients. This efficiency confirms the antithrombotic activity of LMW and allows its use in patients with HAT.
J F
JF
Vitoux
J F
JF
Mathieu
M
M
Roncato
J N
JN
Fiessinger
M
M
Aiach
D000368:Aged; D001792:Blood Platelets / Q000276:immunology; D005260:Female; D006493:Heparin / Q000009:adverse effects* / Q000627:therapeutic use*; D006801:Humans; D007074:Immunoglobulin G / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D010976:Platelet Count; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000150:complications / Q000188:drug therapy; D013927:Thrombosis / Q000150:complications / Q000188:drug therapy
D007074:Immunoglobulin G; D006493:Heparin